B+
Bull case
20%
Probability
Target price
$30.36
Analysis reference price unavailable
Analysis 2026-08-24 · RankAlpha Sentiment Codex
SGMT
Sagimet BiosciencesBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Sagimet has materially improved funding visibility, with management targeting Phase 3 denifanstat initiation in H2 2026 and stating that cash resources should extend through the Phase 3 readout and NDA submission [#SEC-8K-2026-08-11]. A timely trial start and credible acne development path could support substantial upside from the $10.25 anchor.
Posture
Constructive
Lead driver
Sentiment
What changed
1 setup hits (3d) with net bullish as of 2026-09-09.
What can break
Clinical efficacy, safety, enrollment, and execution risk remain high across denifanstat and TVB-3567.
Momentum
96
Value
41
Sentiment
76
Setup hits (3d)
1 · Net Bullish
AI TargetsBase $8.43 · Bull $30.36 · Bear $5.50Analysis 2026-08-24; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-24 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Bullish
Target $29.33
Why
Momentum96 · Δ7d +1.4
Value41 · Δ7d 0.0
Sentiment76 · Δ7d +4.3
So what
Strength-led posture (Net Bullish). Favor watchlist adds and disciplined entries.
Confirming evidence
- • 1 setup hits (3d) with net bullish as of 2026-09-09.
- • Sentiment remains the lead driver in the composite, 7D delta +4.3.
Contradictions & invalidation
- • Clinical efficacy, safety, enrollment, and execution risk remain high across denifanstat and TVB-3567.
- • Denifanstat Phase 3 initiation could be delayed or require additional regulatory interaction.
- • The Q2 EPS miss was small but directionally negative, and the key value drivers remain unproven clinical milestones rather than operating earnings.
Catalyst clock
2026-08-11
Q2 print was broadly on-plan but included a small EPS miss
Lead driver: Sentiment · See AI snapshot
Momentum
96
9% active weight
Current posture
7d trendImproving
Δ7d
+1.4
Δ21d
+1.7
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
76
62% active weight
Current posture
7d trendImproving
Δ7d
+4.3
Δ21d
+41.9
Why this grade
Composite grade B. Momentum 96.3 / Value 41.2 / Sentiment 75.8
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-24. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$8.43
Analysis reference price unavailable
Analysis 2026-08-24 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$5.50
Analysis reference price unavailable
Analysis 2026-08-24 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$638.15M
Beta
-
Shares Out
61.75M
P/E (TTM) · Derived
-6.5
P/S (TTM)
-
P/FCF (TTM) · Derived
-8.98
Rev YoY
-100.0%
EPS YoY
-18.6%
Gross Margin
+98.3%
Op Margin
-1813.8%
Net Debt
-$113.05M
Current Ratio
44.94
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data